Literature DB >> 9012447

A comparison of gene transfer methods in human dendritic cells.

J F Arthur1, L H Butterfield, M D Roth, L A Bui, S M Kiertscher, R Lau, S Dubinett, J Glaspy, W H McBride, J S Economou.   

Abstract

Dendritic cells (DCs) are the most potent antigen-presenting cells (APCs) for the initiation of antigen-specific T-cell activation. DCs may be highly enriched from peripheral blood-adherent leukocytes by short-term (7-day) culture in the presence of interleukin (IL)-4 and granulocyte-macrophage colony-stimulating factor. Various methods of gene transfer were studied, including DNA/liposome complexes, electroporation, CaPO4 precipitation, and recombinant adenovirus (AdV) vectors. Low levels of expression were obtained with the physical methods tested. In contrast, AdV vectors expressing luciferase, beta-galactosidase, IL-2, and IL-7 all readily transduced human DCs. Increasing levels of gene expression were observed over a range of multiplicity of infection (MOI) of 10:1 to 10,000:1, with transduction efficiencies exceeding 95% at higher MOI. Although levels of maximal gene expression in DCs were significantly lower than those obtained using human tumor cell lines, IL-2 and IL-7 production of up to 5 x 10(2) ng/10(6) DC were achieved. These results suggest that AdV vectors are a promising vehicle for genetically engineering human DCs.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9012447

Source DB:  PubMed          Journal:  Cancer Gene Ther        ISSN: 0929-1903            Impact factor:   5.987


  45 in total

Review 1.  RNA-transfected dendritic cells in cancer immunotherapy.

Authors:  D A Mitchell; S K Nair
Journal:  J Clin Invest       Date:  2000-11       Impact factor: 14.808

Review 2.  Dendritic Cell-Based Cancer Vaccines.

Authors:  Patricia M Santos; Lisa H Butterfield
Journal:  J Immunol       Date:  2018-01-15       Impact factor: 5.422

Review 3.  Vaccines to prevent chronic hepatitis C virus infection: current experimental and preclinical developments.

Authors:  Philip Wintermeyer; Jack R Wands
Journal:  J Gastroenterol       Date:  2007-06-29       Impact factor: 7.527

4.  Lentivirally engineered dendritic cells activate AFP-specific T cells which inhibit hepatocellular carcinoma growth in vitro and in vivo.

Authors:  Yang Liu; Lisa H Butterfield; Xiaohui Fu; Zhenshun Song; Xiaoping Zhang; Chongde Lu; Guanghui Ding; Mengchao Wu
Journal:  Int J Oncol       Date:  2011-04-13       Impact factor: 5.650

5.  Therapy of established tumour with a hybrid cellular vaccine generated by using granulocyte-macrophage colony-stimulating factor genetically modified dendritic cells.

Authors:  X Cao; W Zhang; J Wang; M Zhang; X Huang; H Hamada; W Chen
Journal:  Immunology       Date:  1999-08       Impact factor: 7.397

6.  Virally infected and matured human dendritic cells activate natural killer cells via cooperative activity of plasma membrane-bound TNF and IL-15.

Authors:  Lazar Vujanovic; David E Szymkowski; Sean Alber; Simon C Watkins; Nikola L Vujanovic; Lisa H Butterfield
Journal:  Blood       Date:  2010-04-29       Impact factor: 22.113

7.  Maturation of human dendritic cells with Saccharomyces cerevisiae (yeast) reduces the number and function of regulatory T cells and enhances the ratio of antigen-specific effectors to regulatory T cells.

Authors:  Vittore Cereda; Matteo Vergati; Ngar-Yee Huen; Maria Giovanna di Bari; Caroline Jochems; Chiara Intrivici; James L Gulley; David Apelian; Jeffrey Schlom; Kwong Y Tsang
Journal:  Vaccine       Date:  2011-05-11       Impact factor: 3.641

Review 8.  Biological treatment for liver tumor and new potential biomarkers.

Authors:  Maurizio Chiriva-Internati; Fabio Grizzi; Mitchell S Wachtel; Marjorie Jenkins; Raffaele Ferrari; Everardo Cobos; Eldo E Frezza
Journal:  Dig Dis Sci       Date:  2007-08-22       Impact factor: 3.199

9.  Effective induction of therapeutic antitumor immunity by dendritic cells coexpressing interleukin-18 and tumor antigen.

Authors:  Dajing Xia; Shu Zheng; Weiping Zhang; Long He; Qingqing Wang; Jianping Pan; Lihuang Zhang; Jianli Wang; Xuetao Cao
Journal:  J Mol Med (Berl)       Date:  2003-08-21       Impact factor: 4.599

10.  A detailed characterisation of the distribution and presentation of DNA vaccine encoded antigen.

Authors:  Catherine M Rush; Timothy J Mitchell; Paul Garside
Journal:  Vaccine       Date:  2009-12-23       Impact factor: 3.641

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.